23:58 , Jul 15, 2019 |  BC Extra  |  Clinical News

Neon points to PFS, biomarkers as signs of neoantigen activity in single-arm combo trial

With Phase Ib data on its neoantigen cancer vaccine plus Opdivo announced Monday, Neon is the latest company to suggest its immuno-oncology candidate improves on the efficacy of checkpoint inhibitor alone by comparing a single-arm...
23:40 , Jul 2, 2019 |  BC Extra  |  Company News

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

Having gained rights to Incyte’s PD-1 inhibitor, Zai rolled out an immuno-oncology combination strategy it thinks can carve out a space in the crowded Chinese checkpoint inhibitor field. Zai Lab Ltd. (NASDAQ:ZLAB) licensed exclusive rights...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
20:50 , Jun 12, 2019 |  BC Extra  |  Financial News

OrbiMed-backed Prelude raises $60M to take PRMT5 program through clinical POC

With $60 million in new series B funding, Prelude hopes to obtain clinical proof-of-concept data for its lead PRMT5 inhibitor for solid tumors or blood cancers. OrbiMed Advisors and one other undisclosed institutional investor backed...
20:45 , Jun 6, 2019 |  BC Extra  |  Financial News

How Third Rock will deploy $770M in its biggest fund yet

Staff changes and recent trends in private capital dynamics aren’t likely to sway Third Rock Ventures’ strategy as it invests its new $770 million Fund V, the firm’s largest-ever vehicle. The firm will, however, have...
20:23 , Jun 4, 2019 |  BC Extra  |  Clinical News

June 4 ASCO Quick Takes: Sarcoma data for Aadi's nab-sirolimus; plus c-MET inhibitor data for NSCLC

Aadi's ABI-009 leads to 42% ORR in rare sarcoma  Aadi Bioscience Inc. (Pacific Palisades, Calif.) reported at ASCO Monday that nab-sirolimus (ABI-009) led to a confirmed investigator-assessed objective response rate of 42%, all partial responses,...
00:09 , Jun 4, 2019 |  BC Innovations  |  Distillery Techniques

Gemcitabine, Jevtana and Jakavi identified to treat pediatric AML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies identified gemcitabine, Jevtana cabazitaxel and Jakavi ruxolitinib as drugs that could help treat pediatric AML. High throughput screening of a library of...
23:52 , May 30, 2019 |  BC Innovations  |  Emerging Company Profile

Aro delivers bispecifics, siRNAs where others can’t

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers. Therapies...
21:28 , May 24, 2019 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
18:36 , Apr 26, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q; (B) During trading hours in Europe; premarket on U.S. exchange Company Date Pre/post mkt 1Q19...